September 14, 2021
Weil advised Sanofi in its $3.2 billion acquisition of Translate Bio, Inc., a clinical-stage mRNA therapeutics company. The transaction closed on September 14, 2021.
The Weil team that advised Sanofi was led by Mergers & Acquisitions partner Michael J. Aiello and included Mergers & Acquisitions partner Matthew Gilroy and Mergers & Acquisitions associates Iliana Karaoglan, Daniel Sotsky and Emily Ross. The team also included Tax partner Graham Magill; Tax associate Charles Kogel; Executive Compensation & Benefits Head Paul Wessel; Executive Compensation & Benefits counsel Steven Margolis; Executive Compensation & Benefits associate Robin Caskey; Technology & IP Transactions Head Michael Epstein; Technology & IP Transactions associates Lauren Springer, Maryann Thompson and Alex Theuer (Not Yet Admitted in New York); Regulatory Transactions partner Shawn Cooley; Regulatory Transactions counsel John O’Loughlin; Regulatory Transactions associate Nathan Cunningham; Antitrust partner John Scribner; Antitrust counsel Michael Naughton; and Antitrust associate Vivian Wang.